Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10828610 | PMC |
| http://dx.doi.org/10.1002/mdc3.13915 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of L-dopa and DBS on cortical oscillations in Parkinson's disease analyzed by Hidden Markov Model algorithm.
Neuroimage
December 2024
Department of Neurosurgery, Affiliated Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address:
Article Synopsis
- Parkinson's disease (PD) is a movement disorder linked to the degeneration of dopamine-producing neurons, and treatments like Levodopa (L-dopa) and Subthalamic Deep Brain Stimulation (STN-DBS) have distinct effects on brain activity that need further study.
- In a study involving 21 PD patients on L-dopa and 11 patients with STN-DBS, researchers used Magnetoencephalogram (MEG) data to analyze how these treatments impacted brain state dynamics through a statistical method called the Time-delay embedded Hidden Markov Model (TDE-HMM).
- Results showed that L-dopa enhanced motor state and beta wave activity in the brain, correlating
Test, track, treat using wearable sensors for management of Parkinson's disease: 12‑month prospective observational United Arab Emirates study using Parkinson's Kinetograph (EmPark-PKG Study).
J Neural Transm (Vienna)
December 2024
Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 5 Cutcombe Road, London, SE5 9RX, UK.
Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by both motor and non-motor symptoms that necessitate ongoing clinical evaluation and medication adjustments. Home-based wearable sensor monitoring offers a detailed and continuous record of patient symptoms, potentially enhancing disease management. The EmPark-PKG study aims to evaluate the effectiveness of the Parkinson's KinetoGraph (PKG), a wearable sensor device, in monitoring and tracking the progression of motor symptoms over 12 months in Emirati and non-Emirati PD patients.
View Article and Find Full Text PDFBiochemical Sensors for Personalized Therapy in Parkinson's Disease: Where We Stand.
J Clin Med
December 2024
Operative Research Unit of Neurology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Álvaro del Portillo, 200, 00128 Rome, Italy.
Since its first introduction, levodopa has remained the cornerstone treatment for Parkinson's disease. However, as the disease advances, the therapeutic window for levodopa narrows, leading to motor complications like fluctuations and dyskinesias. Clinicians face challenges in optimizing daily therapeutic regimens, particularly in advanced stages, due to the lack of quantitative biomarkers for continuous motor monitoring.
View Article and Find Full Text PDFRisk of fall with device-based advanced treatments in Parkinson's disease: a systematic review and network meta-analysis.
J Neurol Neurosurg Psychiatry
November 2024
Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada
Background: Deep brain stimulation (DBS) and infusion therapies are effective treatments for the motor complications of Parkinson's disease (PD), but less established is their role in fall prevention. This systematic review and network meta-analysis (NMA) aimed to evaluate the risk of falls associated with advanced therapies in PD.
Methods: Following PRISMA-NMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Network Meta-analyses) guidelines, we searched PubMed, Medline, Embase and CINAHL up to 20 March 2024.
LDHzyme-assisted high-performance on-site tracking of levodopa pharmacokinetics for Parkinson's disease management.
Biosens Bioelectron
January 2025
Lab of Functional and Biomedical Nanomaterials, College of Materials Science and Engineering, Qingdao University of Science and Technology (QUST), Qingdao, 266042, PR China. Electronic address:
Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by the loss of dopaminergic neurons and the consequent decline in motor and cognitive functions. The primary therapeutic agent levodopa necessitates precise dosing due to its narrow therapeutic window and complex pharmacokinetics. This study presents the development of a novel CuCoFe-LDHzyme-based sweat sensor for real-time monitoring of levodopa concentration in PD patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!